Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

149.01 -5.05 (-3.28%)
Streaming Delayed Price Updated: 2:41 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle Movement ↗
Neurocrine Biosciences Inc (NASDAQ: NBIX) revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza (valbenazine) for chorea associated with... 
Via Benzinga
News headline image
Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets ↗
Neurocrine Biosciences Inc (NASDAQ: NBIX) has outlined a deal that provides Sosei Heptares Corporation $100 million upfront, R&D expenses, and a... 
Via Benzinga
News headline image
Mobile Mental Health: Coming to a Home Near You? ↗
Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
News headline image
Analyst Ratings For Neurocrine Biosciences ↗
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst rat... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 ↗
Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE: 
Via Benzinga
News headline image
71 Biggest Movers From Yesterday ↗
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales... 
Via Benzinga
News headline image
Why Neurocrine Biosciences Shares Fell Nearly 10% Today ↗
Investors have grown weary of unpredictable profitability and unexpected expenses. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%... 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Neurocrine Biosciences ↗
Over the past 3 months, 5 analysts have published their opinion on Neurocrine Biosciences (NASDAQ: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
News headline image
Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcript ↗
NBIX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Biophytis (NASDAQ:BPTS) shares mo... 
Via Benzinga
News headline image
Neurocrine Biosciences: Q3 Earnings Insights ↗
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Monday, November 1, 2021 at 04:01 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Neurocrine Biosciences's Return On Capital Employed Overview ↗
According to Benzinga Pro, during Q2, Neurocrine Biosciences (NASDAQ:NBIX) earned $62.80 million, a 99.37% increase from the preceding quarter. Neurocrine Biosciences also posted... 
Via Benzinga
News headline image
Looking into Neurocrine Biosciences's Return on Capital Employed ↗
After pulling data from Benzinga Pro it seems like during Q2, Neurocrine Biosciences (NASDAQ:NBIX) earned $62.80 million, a 99.37% increase from the preceding quarter. Neurocrine... 
Via Benzinga
News headline image
Earnings Scheduled For November 1, 2021 ↗
Companies Reporting Before The Bell • ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third quarter. • Kiniksa Pharmaceuticals (NASDAQ:... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 ↗
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday morning, 67 companies achieved new lows for the year. Areas of Significance: Grifols (NASDAQ:GRFS) was the largest firm by market cap to set a new 52-... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 6, 2021 ↗
Upgrades According to Wolfe Research, the prior rating for The AES Corp (NYSE: 
Via Benzinga
News headline image
Neurocrine Biosciences, inc (NBIX) Q2 2021 Earnings Call Transcript ↗
NBIX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Neurocrine Biosciences Inc (NBIX) Q1 2021 Earnings Call Transcript ↗
NBIX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For August 3, 2021 ↗
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to... 
Via Benzinga
Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
Via FinancialNewsMedia
News headline image
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.